Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2004-06-14
2009-02-24
Ouspenski, Ilia (Department: 1644)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
Reexamination Certificate
active
07494779
ABSTRACT:
A method for obtaining agonist, antagonist and inverse agonist, to a given physiological receptor is disclosed. For the method, use is made of in silico design synthetic immunogens, which are caused to act in vitro on human lymphocyte-containing cell populations. A preferred receptor is human CD152, particularly the regions of CDR1, CDR2 and CDR3 that elicit antibodies serving as antagonist, inverse agonist and agonist, respectively. Also provided is a method in the treatment of human peripheral lymphocytes for use in the screening of CD152 ligands that yield pharmacological effects.
REFERENCES:
patent: 5811097 (1998-09-01), Allison et al.
patent: 5855887 (1999-01-01), Allison et al.
patent: 6051227 (2000-04-01), Allison et al.
patent: 6120765 (2000-09-01), Hibino et al.
patent: 6150584 (2000-11-01), Kucherlapati et al.
patent: 6613327 (2003-09-01), Ling et al.
patent: 6682736 (2004-01-01), Hanson et al.
patent: 7229628 (2007-06-01), Allison et al.
patent: 00/32231 (2000-06-01), None
patent: 00/37504 (2000-06-01), None
patent: 01/14424 (2001-03-01), None
Chillaron et al., 2001, Am. J. Physiol. Renal Physiol., 281: F995-F1018.
Gribben et al., Proc. Natl. Acad. Sci. USA, 1995, 92: 811-815.
Hruby V., 2002, Nature Reviews, 1: 847-858 (provided by Applicant).
Hurwitz et al., 2000, Cancer research, 60: 2444-2448 (provided by Applicant).
Phan et al., 2003, PNAS, 100: 8372-8377 (provided by Applicant).
Hodi et al., 2003, PNAS, 100: 4712-4717 (provided by Applicant).
Peter S. Linsley, William Brady, Mrk Urnes, Laura S. Grosmaire, Nitin K. Damle, and Jeffrey A. Ledbetter; CTLA-4 Is a Second Recepotor for the B Cell Activation Antigen B7; Sep. 1991; pp. 561-569.
L.T. Chin, J. Hinkula, M. Levi, M. Ohlin, B. Wahren, C.A.K. Borrebaeck; Site-directed primary in vitro immunization: production of HIV-1 neutralizing human monoclonal antibodies from lymphocytes obtained from seronegative donors; 1994; pp. 428-434.
Lie-Te Chin, Ann-Christin Malmborg, Karin Kristensson, Jorma Hinkula, Britta Wahren, and Carl A.K. Borrebaeck; Mimicking the humoral immune response in vitro results in antigen-specific isotype switching supported by specific autologous T helper cells: generation of human HIV-1 neutralizing IgG monoclonal antibodies form naive donors: 1995; pp. 657-663.
Stephane Demotz, Antonio Lanzavecchia, Ulrich Eisel, Heiner Neimann, Christian Widmann, and Giampietro Corradin; Delineation of Several Dr-restricted Tetanus Toxin T Cell Epitopes; Jan. 15, 1989; pp. 394-402.
Dana R. Leach, Matthew F. Krummel, James P. Allison; Enhancement of antitumor immunity by CTLA-4 blockade; Mar. 22, 1996; pp. 1734-1736.
Chin Li-Te
Hsu Shu-Ching
Bacon & Thomas PLLC
Ouspenski Ilia
LandOfFree
Method for producing human antibodies to human CD152 with... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for producing human antibodies to human CD152 with..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for producing human antibodies to human CD152 with... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4128942